KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Cash Flow (2016 - 2025)

Rigel Pharmaceuticals has reported Net Cash Flow over the past 16 years, most recently at -$8.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$8.0 million for Q4 2025, down 257.38% from a year ago — trailing twelve months through Dec 2025 was -$16.1 million (down 167.23% YoY), and the annual figure for FY2025 was -$16.1 million, down 167.23%.
  • Net Cash Flow for Q4 2025 was -$8.0 million at Rigel Pharmaceuticals, down from -$4.9 million in the prior quarter.
  • Over the last five years, Net Cash Flow for RIGL hit a ceiling of $64.8 million in Q2 2021 and a floor of -$54.4 million in Q3 2021.
  • Median Net Cash Flow over the past 5 years was -$438000.0 (2022), compared with a mean of $513200.0.
  • Peak annual rise in Net Cash Flow hit 839.79% in 2021, while the deepest fall reached 55630.61% in 2021.
  • Rigel Pharmaceuticals' Net Cash Flow stood at -$11.5 million in 2021, then surged by 53.04% to -$5.4 million in 2022, then plummeted by 133.55% to -$12.6 million in 2023, then soared by 140.02% to $5.1 million in 2024, then crashed by 257.38% to -$8.0 million in 2025.
  • The last three reported values for Net Cash Flow were -$8.0 million (Q4 2025), -$4.9 million (Q3 2025), and $7.7 million (Q2 2025) per Business Quant data.